Summary
Nine hundred and eighty-four breast cancer patients were interviewed regarding exogenous hormonal use. This represents a random sample of breast cancer patients in Southern Sweden referred to the Department of Oncology at Lund for treatment between 1978 and 1997 (excluding 1980 and 1981) with a 100% follow-up. Ever-use of hormone replacement therapy (HRT) prior to diagnosis was significantly associated with a longer overall survival in women with their breast cancer diagnosed at ages 45 and above, relative risk (RR) of dying 0.73 (95% confidence interval (CI) 0.62–0.87; P = 0.0005). Ever use of HRT prior to breast cancer diagnosis was significantly positively associated with overall longer survival after adjustment for T-stage, N-stage, M-stage, year of diagnosis and age at diagnosis, RR of dying 0.78 (95% CI 0.65–0.93; P = 0.006). Hormone replacement therapy use and oestrogen receptor positivity were independently significantly associated with overall longer survival, P = 0.005 and P < 0.0001, respectively, in one model. HRT use and progesterone receptor positivity were also independently significantly associated with longer overall survival, P = 0.003 and P = 0.0003, respectively, in another model. The mode of diagnosis was known in 705 women. Mammography screening was not more common among HRT users compared with never-users, where this information was available. Both mammography screening and HRT use were independently associated with longer survival, P = 0.002 and P = 0.038 respectively.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Bergkvist, L., Adami, H-O, Persson, I., Bergström, R. & Krusemo, U. B. (1989). Prognosis after breast cancer diagnosis exposed to estrogen and estrogen–progestogen replacement therapy. Am J Epidemiol 130: 221–228.
Bonnier, P., Romain, S., Giacalone, P. L., Laffargue, F., Martin, P. M. & Piana, L. (1995). Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 85: 11–17.
Brinton, L. A., Hoover, R. & Fraumeni, J. F. Jr (1986). Menopausal oestrogens and breast cancer risk: an expanded case-control study. Br J Cancer 54: 825–832.
Collaborative Group on Hormonal Factors in Breast Cancer: (1997). Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52 705 women with breast cancer and 108 411 women without breast cancer. Lancet 350: 1047–1059.
Fernö, M., Borg, Å & Norgren, A. (1983). A comparison of two steroid receptor assays in breast cancer: dextran coated charcoal and isoelectric focusing. Anticancer Res 3: 243–246.
Fernö, M., Borg, Å & Sellberg, G. (1986). Enzyme immuno assay of the estrogen receptor in breast cancer biopsy samples. A comparison with isoelectric focusing. Acta Radiol Oncol 25: 171–175.
Fernö, M., Borg, Å & Johansson, U. (1989). Enzyme immuno assay of progesterone receptor in breast cancer biopsy samples. A comparison with the dextran coated charcoal method. Acta Oncol 28: 19–22.
Grodstein, F., Stampfer, M. J., Colditz, G. A., Willett, W. C., Manson, J. E., Joffe, M., Rosner, B., Fuchs, C., Hankinson, S. E., Hunter, D. J., Hennekens, C. H. & Speizer, F. E. (1997). Postmenopausal hormone therapy and mortality. N Engl J Med 336: 1769–1775.
Harding, C., Knox, W. F., Faragher, E. B., Baildam, A. & Bundred, N. J. (1996). Hormone replacement therapy and tumour grade in breast cancer: prospective study in screening unit. Br Med J 312: 1646–1647.
Henderson, B. E., Paganini-Hill, A. & Ross, R. K. (1991). Decreased mortality in users of estrogen replacement therapy. Arch Intern Med 151: 75–78.
Hulley, S., Grady, D., Bush, T., Furberg, C., Herrington, D., Riggs, B. & Vittinghoff, E. (1998). Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280: 605–613.
Hunt, K., Vessey, M. & McPherson, K. (1990). Mortality in a cohort of long-term users of hormone replacement therapy: an updated analysis. Br J Obstet Gynecol 97: 1080–1086.
Hunter, D. & Willet, W. (1993). Diet, body size, and breast cancer. Epidemiol Rev 15: 110–132.
Jones, C., Ingram, D., Mattes, E. & Hahnel, R. (1994). The effect of hormone replacement therapy on prognostic indices in women with breast cancer. Med J Aust 161: 106–110.
Magnusson, C., Holmberg, L., Norden, T., Lindgren, A. & Persson, I. (1996). Prognostic characteristics in breast cancers after hormone replacement therapy. Breast Cancer Res Treat 38: 325–334.
Matthews, K. A., Kuller, L. H., Wing, R. R., Meilahn, E. N. & Plantinga, P. (1996). Prior to use of estrogen replacement therapy, are users healthier than non-users?. Am J Epidemiol 143: 971–978.
Nischan, P., Thomas, D. B. & Ebeling, K. (1992). Accuracy of recall of use of an intrauterine device. Contraception 45: 363–368.
Nyström, L., Rutqvist, L. E., Wall, S., Lindgren, A., Lindqvist, M., Ryden, S., Andersson, I., Bjurstam, N., Fagerberg, G., Frisell, J., Tabor, L. & Larsson, L. G. (1993). Breast cancer screening with mammography: overview of Swedish randomised trials. Lancet 341: 973–978.
Olsson, H. & Hägglund, G. (1992). Reduced cancer morbidity and mortality in a prospective cohort of women with distal forearm fractures. Am J Epidemiol 136: 422–427.
Persson, I., Bergkvist, L., Lindgren, C. & Yuen, J. (1997). Hormone replacement therapy and major risk factors for reproductive cancers, osteoporosis, and cardiovascular diseases: evidence of confounding by exposure characteristics. J Clin Epidemiol 50: 611–618.
Salmon, R., Remvikos, Y., Ansquer, Y. & Asselain, B. (1995). HRT and breast cancer. Lancet 346: 1702–1703.
Schairer, C., Byrne, C., Keyl, P. M., Brinton, L. A., Sturgeon, S. R. & Hoover, R. N. (1994). Menopausal estrogen and estrogen-progestin therapy and risk of breast cancer (United States). Cancer Causes Control 5: 491–500.
Sigurdsson, H., Baldetorp, B., Borg, å, Dahlberg, M., Fernö, M., Killander, D. & Olsson, H. (1990). Indicators of prognosis in node-negative breast cancer. N Engl J Med 322: 1045–1053.
Squitieri, R., Tartter, P. I., Ahmed, S., Brower, S. T. & Theise, N. D. (1994). Carcinoma of the breast in postmenopausal hormone user and nonuser control groups. J Am Coll Surg 178: 167–170.
Strickland, D. M., Gambrell, R. D. Jr, Butzin, C. A. & Strickland, K. (1992). The relationship between breast cancer survival and prior postmenopausal estrogen use. Obstet Gynaecol 80: 400–404.
Sullivan, J. M., Vander Zwaag, R., Hughes, J. P., Maddock, V., Kroetz, F. W., Ramanathan, K. B. & Mirvis, D. M. (1990). Estrogen replacement and coronary artery disease. Effect on survival in postmenopausal women. Arch Intern Med 150: 2557–2562.
Willis, D. B., Calle, E. E., Miracle-McMahill, H. L. & Heath, C. W. Jr (1996). Estrogen replacement therapy and risk of fatal breast cancer in a prospective cohort of postmenopausal women in the United States. Cancer Causes Control 7: 449–457.
Yuen, J., Persson, I., Bergqvist, L., Hoover, R., Schairer, C. & Adami, H-O (1993). Hormone replacement therapy and breast cancer mortality in Swedish women: results after adjustment for ‘healthy drug-user’ effect. Cancer Causes Control 4: 369–374.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Jernström, H., Frenander, J., Fernö, M. et al. Hormone replacement therapy before breast cancer diagnosis significantly reduces the overall death rate compared with never-use among 984 breast cancer patients. Br J Cancer 80, 1453–1458 (1999). https://doi.org/10.1038/sj.bjc.6690543
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690543
Keywords
This article is cited by
-
Family history influences the tumor characteristics and prognosis of breast cancers developing during postmenopausal hormone therapy
Familial Cancer (2018)
-
Hormone replacement therapy and breast cancer survival: a systematic review and meta-analysis of observational studies
Breast Cancer (2017)
-
History of oral contraceptive use in breast cancer patients: impact on prognosis and endocrine treatment response
Breast Cancer Research and Treatment (2015)
-
Pre- and postoperative alcohol consumption in breast cancer patients: impact on early events
SpringerPlus (2014)
-
Autoimmune diseases and hypersensitivities improve the prognosis in ER-negative breast cancer
SpringerPlus (2013)